Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
09:03:57 EDT Mon 06 May 2024
Enter Symbol
or Name
USA
CA



News for U:NVAX from 2023-05-07 to 2024-05-06 - 42 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-06 06:23U:NVAXNews ReleaseShah Capital Launches Campaign Urging Stockholders to Vote AGAINST the Re-Election of All of Novavax's Directors Up for Election at its 2024 Annual Meeting
2024-04-15 06:00U:NVAXNews ReleaseShah Capital nominates two highly qualified independent director candidates for Novavax
2024-04-01 08:00U:NVAXNews ReleaseNovavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024
2024-02-29 16:02U:NVAXNews ReleaseNovavax to Participate in TD Cowen's 44th Annual Health Care Conference
2024-02-28 08:00U:NVAXNews ReleaseNovavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
2024-02-22 06:00U:NVAXNews ReleaseNovavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement
2024-02-20 09:25U:NVAXNews ReleaseNovavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024
2024-01-03 09:25U:NVAXNews ReleaseNovavax to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-18 08:00U:NVAXNews ReleaseNovavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan
2023-12-13 08:00U:NVAXNews ReleaseCanadians Can Help Protect Loved Ones as We Head into the Holiday Season
2023-12-05 16:01U:NVAXNews ReleaseNovavax's Updated COVID-19 Vaccine Now Authorized in Canada
2023-12-05 16:01U:NVAXNews ReleaseNovavax's Updated COVID-19 Vaccine Now Authorized in Canada
2023-11-28 06:00U:NVAXNews ReleaseNovavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization
2023-11-17 07:15U:NVAXNews ReleaseNovavax Makes Changes to Executive Leadership Team to Enhance Focus on Delivery of Strategic Priorities
2023-11-10 09:25U:NVAXNews ReleaseNovavax to Participate in Jefferies London Healthcare Conference
2023-11-09 08:00U:NVAXNews ReleaseNovavax Reports Third Quarter 2023 Financial Results and Operational Highlights
2023-11-02 09:25U:NVAXNews ReleaseNovavax to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Operational Highlights on November 9, 2023
2023-10-31 16:37U:NVAXNews ReleaseNovavax's Updated COVID-19 Vaccine Now Approved in the EU
2023-10-31 12:58U:NVAXNews ReleaseNovavax's Updated Nuvaxovid ¢ „ ¢ COVID-19 Vaccine Receives Positive CHMP Opinion in the EU
2023-10-18 08:05U:NVAXNews ReleaseNovavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid ¢ „ ¢ ¢ – ¼ in United Kingdom
2023-10-18 08:00U:NVAXNews ReleaseNovavax's Prototype COVID-19 Vaccine Nuvaxovid ¢ „ ¢ Receives Full Approval in Singapore
2023-10-13 09:29U:NVAXNews ReleaseNovavax COVID-19 Vaccine Doses Available at Major Retail Pharmacies Across the U.S.
2023-10-11 08:00U:NVAXNews ReleaseNovavax Advances Science Supporting Protein-based Vaccine Technology at IDWeek 2023 and World Vaccine Congress Europe 2023
2023-10-10 09:06U:NVAXNews ReleaseNovavax Launches Choose to Protect ¢ „ ¢ Campaign to Educate Public About Importance of Updated COVID Vaccination this Fall
2023-10-03 15:50U:NVAXNews ReleaseNovavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.
2023-10-03 15:50U:NVAXNews ReleaseNovavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.
2023-09-08 16:31U:NVAXNews ReleaseNovavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
2023-09-08 12:00U:NVAXNews ReleaseNovavax to Participate in Upcoming September Conferences
2023-08-22 07:00U:NVAXNews ReleaseNovavax's Updated Protein-based XBB COVID Vaccine Induced Neutralizing Responses Against Emerging Subvariants, Including EG.5.1 and XBB.1.16.6
2023-08-08 08:00U:NVAXNews ReleaseNovavax Reports Second Quarter 2023 Financial Results and Operational Highlights
2023-08-01 09:25U:NVAXNews ReleaseNovavax to Host Conference Call to Discuss Second Quarter 2023 Financial Results and Operational Highlights on August 8, 2023
2023-07-06 09:47U:NVAXNews ReleaseNovavax's Nuvaxovid ¢ „ ¢ Receives Full Marketing Authorization in the EU for the Prevention of COVID
2023-06-15 17:30U:NVAXNews ReleaseNovavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall
2023-06-15 09:06U:NVAXNews ReleaseNovavax Announces Adjournment of 2023 Annual Meeting of Stockholders to July 11, 2023
2023-06-15 09:05U:NVAXNews ReleaseNovavax Announces Adjournment of 2023 Annual Meeting of Stockholders to July 11, 2023
2023-06-05 08:00U:NVAXNews ReleaseNovavax Announces Agreement with Bill & Melinda Gates Medical Research Institute to Include Matrix-M ¢ „ ¢ Adjuvant as Potential Component in Vaccine Research
2023-06-01 16:02U:NVAXNews ReleaseNovavax to Participate in the Jefferies Global Healthcare Conference
2023-05-26 09:29U:NVAXNews ReleaseNovavax's Nuvaxovid ¢ „ ¢ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU
2023-05-12 09:00U:NVAXNews ReleaseAccess to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore
2023-05-09 06:30U:NVAXNews ReleaseNovavax Reports First Quarter 2023 Financial Results and Operational Highlights
2023-05-09 06:28U:NVAXNews ReleasePositive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses
2023-05-09 06:28U:NVAXNews ReleasePositive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses